Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

DLC-1 Expression Levels in Breast Cancer Assessed by qRT-PCR are Negatively Associated with Malignancy

  • Guan, Cheng-Nong (Department of Oncology, the Affiliated Hospital of Guangdong Medical College) ;
  • Zhang, Pei-Wen (Department of Oncology, the Affiliated Hospital of Guangdong Medical College) ;
  • Lou, Hai-Qing (Department of Oncology, the Affiliated Hospital of Guangdong Medical College) ;
  • Liao, Xiang-Hui (Department of Oncology, the Affiliated Hospital of Guangdong Medical College) ;
  • Chen, Bao-Ying (Department of Oncology, the Affiliated Hospital of Guangdong Medical College)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The aim of this study was to explore the expression of DLC-l in breast carcinoma and any association with tumor metastasis. Methods: 51 surgical specimens of human breast carcinoma, divided into high invasive and low invasive groups according to their clinicopathological features, 30 cases of adjacent normal tissue and 28 benign breast lesions were examined by qRT-PCR for expression of DLC-1. Results: Expression level of DLC-1 in adjacent normal tissue and benign breast lesion specimens was higher than that in breast carcinoma (P<0.0001); the values in the high invasive group with synchronous metastases were also lower than in the low invasive group (P=0.0275). The correlation between DLC-1 expression level and tumor progression and metastasis of breast cancer was negative. Conclusion: As an anti-oncogene, DLC-1 could play an important part in breast carcinoma occurrence, progression, invasiveness and metastasis. Detecting the changes of the expression of DLC-1 in the breast carcinoma may contribute to earlier auxiliary diagnosis of invasiveness, metastasis and recrudescence.

Keywords

References

  1. Durkin ME (2002). Gene structure, tissue expression and linkage mapping of the mouse DLC-1 gene (Arhgap7). Gene, 17, 119-23.
  2. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC (2006). Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res, 12, 1412-9. https://doi.org/10.1158/1078-0432.CCR-05-1906
  3. Kim TY, Jong HS, Song SH, et al (2003). Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene, 22, 3943-51. https://doi.org/10.1038/sj.onc.1206573
  4. Kim TY, Lee JW, Kim HP, et al (2007). DLC-1, a GTPaseactivating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun, 355, 72-7. https://doi.org/10.1016/j.bbrc.2007.01.121
  5. Liu JB, Zhang SQ, Shi MX, Cai J (2008). Clinical value of the expression of the DLC-1 in hepatocellular carcinoma. J Modern Lab Med, 23, 76-8.
  6. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D (2004). Part I: Vaccines for solid tumours. Lancet Oncol, 5, 681-9. https://doi.org/10.1016/S1470-2045(04)01610-9
  7. Park SW, Durkin ME, Thorgeirsson SS, Popescu NC (2003). DNA variants of DLC-1, a candidate tumor suppressor gene, in human hepatocellular carcinoma. Int J Oncol, 23, 133-7.
  8. Plaumann M, Seitz S, Frege R, Estevez-Schwarz L, Scherneck S (2003). Analysis of DLC-1 expression in human breast cancer. Cancer Res Clin Oncol, 129, 349-54. https://doi.org/10.1007/s00432-003-0440-z
  9. Qian X, Li G, Asmussen HK, et a1 (2007). Oncogenic inhibition by adeleted in liver cancer gene requires cooperation between tensinbinding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA, 104, 9012-7. https://doi.org/10.1073/pnas.0703033104
  10. Sacha JH, Elizabeth A (2008). Prolactin receptor antagonism reduces theclonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res, 10, R68. https://doi.org/10.1186/bcr2129
  11. Sekimata M, Kabuyama Y, Emori Y, Homma Y (1999). Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. J Biol Chem, 274, 17757-62. https://doi.org/10.1074/jbc.274.25.17757
  12. Seng TJ, Low JS, Li H, et al (2007). The major 8p22 tumor suppressorDLC1 is frequently silenced by methylation in both endemic andsporadic nasopharyngeal, esophageal, and cervical carcinomas, andinhibits tumor cell colony formation. Oncogene, 26, 934-44. https://doi.org/10.1038/sj.onc.1209839
  13. Shang YF, Jin YL, Xu JJ, Li N, Huang PL (2008). Effect of DLC-1 gene on invasion and migration of human colorectal cancer cell line. Progress Modern Biomed, 8, 19-21.
  14. Wong CM, ee JM, Ching YP, et al (2003). Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res, 63, 7646-51.
  15. Wong CM, Yam JW, Ching YP, et al (2005). Rho GTPaseactivating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res, 65, 8861-8. https://doi.org/10.1158/0008-5472.CAN-05-1318
  16. Yam JW, Ko FC, Chan CY, Jin DY, Ng IO (2006). Interaction of deleted in liver cancer 1 with tensin in caveolaeand implications in tumor suppression. Cancer Res, 66, 8367-72. https://doi.org/10.1158/0008-5472.CAN-05-2850
  17. Yin HL, Janmey PA (2003). Phosphoinositide regulation of the actin cytoskeleton. Annu Rev Physiol, 65, 761-89. https://doi.org/10.1146/annurev.physiol.65.092101.142517
  18. Yuan BZ, hou X, urkin ME, et al (2003). DLC-1gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene, 23, 445-50.
  19. Yuan BZ, Jefferson AM, Baldwin TK, et a1 (2004). DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene, 237, 1405-11.
  20. Yuan BZ, Burkin ME (2003). Promoter hypermethylation of DLC-1, candidate tumor suppressor gene, n several common human cancers. Cancer Genet Cytogenet, 15, 113-7.
  21. Zhou X, Thorgeirsson SS, Popescu NC (2004). Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene, 23, 1308-13. https://doi.org/10.1038/sj.onc.1207246

Cited by

  1. DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma vol.34, pp.5, 2013, https://doi.org/10.1007/s13277-013-0813-0
  2. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma vol.34, pp.5, 2013, https://doi.org/10.1007/s13277-013-0846-4
  3. Expression of DNMTs and genomic DNA methylation in gastric signet ring cell carcinoma vol.8, pp.3, 2013, https://doi.org/10.3892/mmr.2013.1566
  4. Deleted in Liver Cancer-1 (DLC1): An Emerging Metastasis Suppressor Gene vol.18, pp.3, 2014, https://doi.org/10.1007/s40291-014-0086-3
  5. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell’s Journey vol.7, pp.3, 2014, https://doi.org/10.1007/s12307-014-0148-4
  6. Clinicopathological Significance of DLC-1 Expression in Cancer: a Meta-Analysis vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7255
  7. 8p deletion is strongly linked to poor prognosis in breast cancer vol.16, pp.7, 2015, https://doi.org/10.1080/15384047.2015.1046025